CEACAM5 and neoplasm: Therefore, the modern translational research paradigm has evolved, placing a large emphasis on biomarker discovery programmes aiming to identify novel biomarkers capable of rivalling current conventional biomarkers used to clinically predict relapse risk (i.e., extramural vascular invasion (EMVI), tumour budding, and carcinoembryonic antigen (CEA), etc.,) [14,15,16].